Europe
Novartis plunked down $650 million in upfront payment for BeiGene’s Tislelizumab, which is already approved for patients with classical Hodgkin’s lymphoma and metastatic urothelial carcinoma in China.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 12, 2021.
On Friday, the U.S. Food and Drug Administration (FDA) issued an official alert stating that it could trigger false negatives in COVID-19 tests.
The deal adds Kymab’s lead asset KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L.
The lessons learned from the global pandemic are expected to translate to existing and emerging therapeutic areas - particularly oncology; more efficient regulatory-industry relationships; mRNA is a word we will continue to hear a lot about; and home health care is here to stay.
The new year began with a fairly low level of clinical trial news. Here’s a look.
News, much of it good, keeps coming in about the efficacy of the various COVID-19 vaccines. Here’s a look.
Merck KGaA buys Amptec for mRNA tech and Chimerix acquires Oncoceutics for cancer pipeline.
BioSpace spoke to executives from four companies about their expectations for the conference and the coming year.
Here’s a run-down of some of the most recent collaboration announcements this week.
PRESS RELEASES